LPTX Leap Therapeutics, Inc.

6.95
+0.17  (3%)
Previous Close 6.78
Open 6.75
Price To book 0.00
Market Cap 65.27M
Shares 9,392,000
Volume 8,170
Short Ratio 0.58
Av. Daily Volume 26,086

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due at ASCO June 3, 2017. Abstract 4075.
DKN-01
Biliary tract cancer (BTC)
Phase 1/2 enrolling as of January 2017.
DKN-01
Esophageal cancer
Phase 3 data fail October 2015
CureXcell
Diabetic Foot Ulcers
Phase 3 endpoint not expected to be met - August 19, 2015.
CureXcell
Venous Leg Ulcers